By: John Cramer
Seasoned followers of my biotech stock recommendations know the incredible returns they’ve reaped. Let’s recap some recent triumphs:
My top coverages include:
Insmed Incorporated (INSM): Recommended at $24, now soaring past $70 – a staggering 300% gain in mere months.
Regeneron Pharmaceuticals (REGN): An early pick at $280, consistently climbing to over $1,200 today – that’s a whopping 400% return.
Summit Therapeutics (SMMT): my 2024 crown jewel, alerted 4 months ago at $3 and skyrocketing to $30+, turning savvy investors into millionaires by generating gains of over 1,000%.
While those ships have sailed, I’ve uncovered a hidden gem poised for explosive growth:
TC Biopharm (Ticker: TCBP)
TCBP surged 80% recently, but this is just the beginning. Here’s why TCBP tops my 2024 watchlist:
Research using artificial intelligence (AI) has become one of the most significant applications of AI technologies in recent years. This approach is revolutionizing the way we conduct scientific studies, particularly in fields like medicine and drug development.
AI-powered research is transforming the traditional scientific process by:
Simulating years of experiments in a fraction of the time
Analyzing vast amounts of data quickly and accurately
Identifying patterns and connections that humans might miss
The use of virtual environments is key to this acceleration:
Digital Simulations: Complex biological processes can be modeled and tested without physical labs.
Rapid Iterations: Thousands of scenarios can be run simultaneously, speeding up the discovery process.
Cost-Effective: Reduces the need for expensive equipment and materials.
By leveraging AI, biotech companies can discover potential new drugs and therapies more rapidly and prioritize the most promising candidates for further development
This approach not only saves time and resources but also has the potential to bring life-saving treatments to patients much faster than traditional methods.
TCBP is working on two potential blockbuster treatments: a groundbreaking cancer therapy that could reshape oncology and a monkey pox treatment which is now in the phase of clinical studies and which looks like a game-changer.
Positioned to make waves in two critical medical fields simultaneously, TCBP is the ticker to watch.
TC Biopharm exhibits the hallmarks of a future ten-bagger, reminiscent of my previous recommendations.
For investors entering now, the potential for quadruple-digit returns is tantalizing.
At just around $8 per share, the time to buy shares of TCBP is right now, before it shoots up higher
